MRC1 and neoplasm: This treatment resulted in a significantly delayed LLC‐OVA tumor growth as compared to the control groups that either only received bivalent anti‐MMR Nb (Figure 8B) or received BCII10 Nb‐IMDQ (Figure 8C) instead of anti‐MMR Nb‐IMDQ.